Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVITA: epcoritamab + venetoclax + ibrutinib in untreated TP53-altered CLL/SLL
2025-520893-20-00Phase 2Authorised
- Sponsor
- LYSARC
- Start
- Oct 2026
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab, venetoclax and ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by LYSARC. Primary endpoint: Complete remission rate and undetectable minimal residual disease. Planned start Oct 2026; status: authorised.
02
Drugs
epcoritamabvenetoclaxibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2025-520893-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520893-20-00.